Navigation Links
XTENT Announces 2007 Financial Results
Date:2/19/2008

MENLO PARK, Calif., Feb. 19 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the fourth quarter and year ended December 31, 2007.

The company reported a net loss and net loss attributable to common stockholders of $11.9 million, or $0.52 per share, for the fourth quarter of 2007, compared to a net loss and net loss attributable to common stockholders of $7.2 million, or $2.46 per share, for the same period in 2006. The company's net loss per share attributable to common stockholders for the fourth quarter of 2007 was based on weighted average shares outstanding of 22.8 million as compared to 2.9 million weighted average shares outstanding for the quarter ended December 31, 2006.

For the year ended December 31, 2007, XTENT had a net loss of $38.8 million, compared to $25.0 million for the same period in 2006. The net loss attributable to common stockholders was $38.8 million for the year ended December 31, 2007, compared to $38.1 million for the same period in 2006. At December 31, 2007, XTENT had cash, cash equivalents and short-term investments of $57.8 million.

Research and development expenses increased to $9.2 million in the fourth quarter of 2007 from $5.5 million for the same period in 2006, primarily due to an increased number of research and development personnel, expenditures for prototype parts and supplies as well as costs incurred for clinical trials. General and administrative expenses were $3.4 million in the fourth quarter of 2007 versus $2.0 million for the same period in 2006, primarily due to an increase in personnel costs related to the hiring of additional employees as well as consulting and professional services associated with operating as a public company.

Research and development expenses for the year ended December 31, 2007, totaled $30.9 million, compared to $18.9 million for the same period in 2006. General and administrative expenses for the year ended December 31, 2007, totaled $11.3 million, compared to $7.3 million for the same period in 2006.

"2007 was a year of tremendous progress for XTENT as we reported additional positive clinical data from our CUSTOM I and CUSTOM II trials, and completed enrollment in our CUSTOM III clinical trial," said Gregory D. Casciaro, XTENT's President and CEO. "We expect 2008 to be a very exciting year for the company as we prepare for CE Mark approval and commercial launch in Europe in the second half of the year. We are actively working on responses to the questions we received from the Food and Drug Administration regarding our IDE submission and expect to commence enrollment in our U.S. clinical trial later this year."

In addition to moving ahead with commercialization and regulatory goals, the company expects to announce long-term follow-up data from its CUSTOM I and CUSTOM II trials, as well as six month data and one year data from the CUSTOM III trial.

The company expects to have operating expenses in the range of $25 to $30 million during the first half of 2008.

2007 Highlights

In 2007, XTENT:

-- Raised over $68 million upon completion of its Initial Public Offering

-- Presented positive six-month follow-up data from the CUSTOM II clinical

trial, which assessed the safety and efficacy of the company's Custom

NX(R) drug-eluting stent (DES) system for the treatment of long and

multiple lesions in patients with coronary artery disease, at a

late-breaking session at the EuroPCR meeting in May

-- Presented positive two-year follow-up data from the CUSTOM I clinical

trial and positive one-year follow-up data from the CUSTOM II clinical

trial, both at TCT in October

-- Completed enrollment of the CUSTOM III clinical trial

-- Introduced design enhancements to the Custom NX DES system to allow for

greater ease-of-use by clinicians

-- Submitted an IDE application to the FDA to initiate its CUSTOM IV

clinical trial

-- Submitted the design dossier for CE Mark

-- Expanded its Menlo Park, California facilities to prepare for

manufacturing ramp-up

Conference Call and Webcast Information

The company will hold a conference call today at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm or by calling 877 627-6580 (domestic), 719 325-4903 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.

An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of its regulatory filings, the timing of regulatory approvals, the timing of the commercialization of its products and the timing of the initiation of its U.S. clinical trial. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended September 30, 2007. This quarterly report was filed with the SEC on November 2, 2007, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

XTENT, INC.

(a development stage company)

Condensed Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Operating expenses:

Research and development (1) $9,194 $5,520 $30,888 $18,923

General and administrative (1) 3,375 1,981 11,269 7,258

Total operating expenses 12,569 7,501 42,157 26,181

Loss from operations (12,569) (7,501) (42,157) (26,181)

Interest and other income, net 705 336 3,363 1,137

Net loss (11,864) (7,165) (38,794) (25,044)

Deemed dividend related to

beneficial conversion feature of

redeemable convertible preferred

stock - - - (13,095)

Net loss attributable to common

stockholders $(11,864) $(7,165) $(38,794) $(38,139)

Net loss per share attributable to

common stockholders - basic and

diluted $(0.52) $(2.46) $(1.87) $(13.96)

Weighted-average common shares

outstanding used in per share

calculation 22,790 2,909 20,703 2,732

(1) Includes the following stock-

based compensation charges:

Research and development $460 $408 $1,490 $1,258

General and administrative $766 $408 $2,088 $986

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

December 31, December 31,

2007 2006

Cash and cash equivalents and short

term investments $57,760 $23,105

Working capital 54,581 21,066

Total assets 62,415 27,121

Redeemable convertible preferred stock - 75,593

Deficit accumulated during the

development stage (92,860) (54,066)

Total stockholders' equity (deficit) 58,331 (50,780)


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New study shows extent of harmful human influences on global ecosystems
2. XTENT Announces 2007 Financial Results Conference Call
3. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
4. XTENT Announces Third Quarter 2007 Financial Results
5. VA Secretary Announces New Walla Walla Facility
6. TrailBlazer Announces Final Medicare Administrative Contractor Schedule for Claims Processing in Four States
7. Pennsylvania Department of Public Welfare Announces Grant Opportunity for Regional Autism Centers
8. Paine & Partners, LLC Announces Sale of Byram Healthcare to OPG Groep N.V.
9. MedCath Announces Venture With Two New Jersey Hospitals
10. Nu Skin Enterprises Announces Increase in Quarterly Dividend
11. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: